Carolin P. Schneider
Goettingen, NI, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam.
Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam.
Journal: Cancer research communications
Published: October 27, 2025
Pan-ERBB Inhibitors Synergize With KRAS Inhibitors in Rectal Cancer.
Journal: United European gastroenterology journal
Published: April 04, 2025
Proteasome inhibition as a potential therapeutic target in thymic cancer.
Journal: Cell death & disease
Published: January 08, 2025
PRMT5 inhibitors: Therapeutic potential in pancreatic cancer.
Journal: Translational oncology
Published: November 25, 2024
Worse survival of hepatocellular cancer patients with membranous insulin receptor overexpression.
Journal: Scientific reports
Published: September 05, 2024
SeqCAT: Sequence Conversion and Analysis Toolbox.
Journal: Nucleic acids research
Published: March 23, 2024
Corrigendum to "A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer" [Bioorgan. Chem. 119 (2022) 105505].
Journal: Bioorganic chemistry
Published: March 08, 2024
Stress granules-membraneless organelles as therapeutic targets in pancreatic cancer.
Journal: EMBO molecular medicine
Published: February 05, 2024
KRASG 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening.
KRASG 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening.
Journal: Molecular oncology
Published: November 03, 2023
Last Updated: 09/26/2026